Immediately preoperative use of biological therapy does not influence liver regeneration after large resection--porcine experimental model with monoclonal antibody against epidermal growth factor.
暂无分享,去创建一个
J Racek | T. Skalický | V. Liska | V. Treska | H. Mírka | A. Sutnar | O. Vyčítal | J. Br̊uha | P. Pitule | A. Chlumská | J. Rácek | L. Holubec | L Holubec | V Treska | J Finek | L. Trefil | J. Finek | V Liska | H Mirka | J Benes | O Vycital | J Bruha | P Pitule | T Skalicky | A Sutnar | A Chlumska | L Trefil | J. Beneš
[1] N. Fausto,et al. Mechanisms of liver regeneration and their clinical implications. , 2005, Journal of hepato-biliary-pancreatic surgery.
[2] J. Vauthey,et al. Perioperative chemotherapy for resectable hepatic metastases , 2008, The Lancet.
[3] O. Fiala,et al. Interleukin-6 augments activation of liver regeneration in porcine model of partial portal vein ligation. , 2009, Anticancer research.
[4] F. Giuliante,et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] Thomas Gruenberger,et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.
[6] P. Morel,et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary , 2006, The British journal of surgery.
[7] David Mangnall,et al. The molecular physiology of liver regeneration following partial hepatectomy , 2003, Liver international : official journal of the International Association for the Study of the Liver.
[8] W. Jarnagin,et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases , 2003, Journal of Gastrointestinal Surgery.
[9] C. Giovane,et al. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer , 2011, British Journal of Cancer.
[10] S. Sorscher. Biological therapy update in colorectal cancer , 2007, Expert opinion on biological therapy.
[11] H. Petrowsky,et al. Strategies for safer liver surgery and partial liver transplantation. , 2007, The New England journal of medicine.
[12] G. Michalopoulos. Liver regeneration: alternative epithelial pathways. , 2011, The international journal of biochemistry & cell biology.
[13] J. Weitz,et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. , 2010, The Lancet. Oncology.
[14] W. Hawkins,et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. , 2005, Journal of the American College of Surgeons.
[15] G. Poston. The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[16] T. Pawlik,et al. Chemotherapy‐associated hepatotoxicity and surgery for colorectal liver metastases , 2007, The British journal of surgery.
[17] A. Panduro,et al. Treatment with anti-tumor growth factor β antibodies influences an altered pattern of cytokines gene expression in injured rat liver , 1998 .
[18] L. Rubbia‐Brandt,et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] H. Hurwitz,et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. , 2008, Journal of the American College of Surgeons.
[20] V. Paradis,et al. Preoperative Liver Hypertrophy Induced by Portal Flow Occlusion Before Major Hepatic Resection for Colorectal Metastases Can Be Impaired by Bevacizumab , 2009, Annals of Surgical Oncology.
[21] P. Metrakos,et al. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[22] C. Köhne,et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] E. Van Cutsem,et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] N. Kemeny. Presurgical chemotherapy in patients being considered for liver resection. , 2007, The oncologist.
[25] H. Schlitt,et al. Intraportal injection of porcine multipotent mesenchymal stromal cells augments liver regeneration after portal vein embolization. , 2009, In vivo.
[26] W. Blonski,et al. Safety of biologic therapy. , 2007, Inflammatory bowel diseases.
[27] M. Gonen,et al. Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study , 2007, Annals of Surgical Oncology.
[28] Lukas Wagner,et al. A Greedy Algorithm for Aligning DNA Sequences , 2000, J. Comput. Biol..
[29] S. Curley,et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] G. Michalopoulos. Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. , 2010, The American journal of pathology.
[31] P. Jeffrey,et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.
[32] L. Rubbia‐Brandt,et al. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. , 2006, Journal of the American College of Surgeons.
[33] T R Fleming,et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. Parmar,et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] E. Abdalla,et al. Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases , 2008, Annals of Surgical Oncology.
[36] L. Ellis,et al. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] R. J. Haas,et al. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases , 2011, The British journal of surgery.
[38] M. Ducreux,et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.